Proteonomix Inc. (PROT)

[Sheeple O Plenty]

To get the necessary cash-flow, PROT has either to sell shares to Venture Funds or selling Convertible-Notes to Venture Funds. Both of them will be dilutive, which per-se is not negative however if you get financed through a Toxic you are out.

Where did the money come from to complete the current Human Clinical Trial?

I am not here to question the product(s) of PROT , however I am realistic enough to know, that clinical trials can take years (you go through 3 phases before you become commercial)

Not always true! For one, research "Orphan Products Development." Also, if the components to the trial are already FDA approved, then Phase 1 does not need to be done, as side effects are already known.

Here, let me help you a bit as your DD seems to be flawed.

The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

This quote from you is especially laughable.

Prot should concentrate their efforts in the anti-aging market which is overcrowded as well, however you won’t have the FDA in your neck and is a multi-billion $ market easier to penetrate as in the search for a solution to cure liver disease.

Please explain to me how an anonymous poster on a paid subscription chat board knows more than this man?

Ian McNiece
Ph.D., Chief Scientific Officer, Director
Dr. McNiece received his PhD in 1986 from the University of Melbourne undertaking his thesis work in studies of blood cell development at the Peter MacCallum Cancer Institute in Melbourne, Australia.

He moved to the USA in July of 1986 to the University of Virginia as a postdoctoral fellow. In August 1998 he started working at Amgen Inc, as a Research Scientist and then as a Laboratory Head.

In September 1997, he left Amgen and moved to the University of Colorado as the Director of Research in the Bone Marrow Transplant Program. Subsequently, he moved to Johns Hopkins University as a Professor of Oncology and Laboratory Director of the Graft Engineering Laboratory from January 2003 to May 2007.

This laboratory is responsible for all processing of bone marrow, peripheral blood progenitor cell (PBPC) products and cord blood products for transplantation of cancer patients. He was actively involved in optimization of cellular grafts for patient treatment and the translation of basic research to clinical treatment.

In July, 2007 he joined the Stem Cell Institute at the University of Miami as Director of the Experimental and Clinical Cell-Based Therapies and is presently Professor of Medicine at the University of Miami.

Dr. Ian McNiece, PhD, Director of the Experimental and Clinical Cell-Based Therapies Department, and Professor of Medicine put his neck on the line to (a) Get the University of Miami to do an FDA Human Clinical Trial and to (b) pay for 97% of the Trial in exchange for 3% of the royalties from the product.

Why do you suppose they did that???? Does a University habitually THROW away money? I think not.


In the future, please use paragraphs. Walls of text are impossible to read coherently. In addition it's much easier to poke holes in faulty arguments when you use paragraphs.